# Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

> **NCT02931565** · PHASE2 · TERMINATED · sponsor: **Cyclerion Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Achalasia

## Interventions

- **DRUG:** Olinciguat
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT02931565
- **Lead sponsor:** Cyclerion Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-06
- **Primary completion:** 2018-05-01
- **Final completion:** 2018-05-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study was prematurely terminated due to enrollment challenges.
- **Last updated:** 2021-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02931565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02931565, "Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02931565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*